Ar, M. CemBuyuktas, DeramEskazan, A. EmreAydin, Seniz OngorenTanrikulu, EdaBaslar, ZaferBuyru, A. Nur2024-04-242024-04-2420121300-77771308-5263https://doi.org/10.5505/tjh.2012.58751https://hdl.handle.net/11468/20165Objective: Bone marrow fibrosis is the second most common complication that causes morbidity and mortality in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs). The aim of this study was to investigate the association between JAK2V617F mutation and bone marrow fibrosis at diagnosis in patients with MPNs. Material and Methods: In total, 149 patients with MPNs were retrospectively evaluated to determine if there was an association between the histological grade of bone marrow fibrosis and JAK2V617F mutation. Results: In all, 67.7% of the patients carried the mutated JAK2 gene. The presence of JAK2V617F mutation was not associated with the occurrence of bone marrow fibrosis (P = 0.55) or its grade at diagnosis (P = 0.65). Conclusion: Molecular mechanisms or genetic defects other than JAK2V617F may underlie the occurrence of bone marrow fibrosis in patients with MPNs.eninfo:eu-repo/semantics/openAccessJak2v617fMyeloproliferative DiseaseBone Marrow FibrosisArticle293242247WOS:0003139358000072474466710.5505/tjh.2012.58751Q4